Skip to main content
. Author manuscript; available in PMC: 2019 Apr 11.
Published in final edited form as: Cell Host Microbe. 2018 Mar 29;23(4):549–556.e3. doi: 10.1016/j.chom.2018.03.001

Figure 4. I.n. RVG9R-siFvEJW treatment induces long-lasting sterilizing immunity to WNV.

Figure 4.

(A) Experimental timeline for re-challenge studies. (B) Kaplan-Meier survival curves of RVG9R-siFvEJW treated C3H mice challenged for a second time with 100LD50 WNV either 1 or 6 months after primary challenge. n= 5-8 mice per group. (C) Serum PRNT90 of C3H mice on day 21 after the second WNV challenge (Post 2°), im munization with H2O2-inactivated WNV (WNVinact) or at 6 months after primary challenge (Pre 2°). Each data point represents one mouse. Bars are geometric mean values. ns- non-significant. (D) Data depicting proportion of mice positive for the specified clinical or virologic parameter. siFvEJW refers to mice treated with i.n. RVG-9R-siFvEJW at days 5 and 6 p.i., a,b-Positive for WNV RNA on day 4 or 8 after challenge; c,d,e-Positive for infectious WNV on day 4, 8 or 30 after challenge, nd- not determined. See also Figure S4.